Three studies presented at the 2014 San Antonio Breast Cancer Symposium (SABCS): Cancer risk test detected 105% more mutations in cancer-causing genes than conventional BRCA testing alone; researchers at leading cancer research institutions validate use of companion diagnostic test to detect a DNA scar in tumor that is indicative of a dysfunctional DNA repair pathway; UK researchers evaluated the use of companion diagnostic assays to identify which patients would respond to carboplatin or docetaxel.
The addition of bevacizumab to standard presurgery chemotherapy showed greater benefit in those whose cancers were classified as basal-like by gene expression assay, compared with those whose cancers were nonbasal-like.
Results from the largest series of male breast cancer cases ever studied shows improvement in male survival, but not equal to that seen in women with breast cancer.
Among women with denser breasts, an additional ultrasound can detect breast cancers not discovered by mammogram.
A multigene test was validated as a predictor of risk of disease recurrence among women treated with breast-conserving surgery alone for ductal carcinoma in situ (DCIS), according to data from a large study.
Pictilisib and pembrolizumab may prolong survival for women with advanced breast cancer, according to data from preliminary studies.
Among premenopausal women with early stage, HR-positive breast cancer, the addition of ovarian suppression to tamoxifen reduced breast cancer recurrence.
The International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium.
Although survival in male breast cancer has improved, treatment lags behind when compared to the cancer therapy women receive.
Pembrolizumab was well tolerated and yielded durable responses in patients with metastatic triple-negative breast cancer, according to recent trial data.
In elderly patients with moderate- to high-risk early stage breast cancer for whom standard chemotherapy is too toxic, capecitabine did not improve outcomes when tested as monotherapy, according to recent data.
Adding tamoxifen to ovarian suppression doesn't provide a significant benefit over tamoxifen alone among premenopausal women with hormone receptor-positive early breast cancer, but the addition of ovarian suppression does benefit some of these women.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|